WW INTERNATIONAL, INC. — Form 8-K
Filed August 5, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
WW International reported Q2 2026 revenue of $162.3M with Clinical Subscription Revenue growing 30.4% YoY to $39.9M (197K clinical subscribers, +55.7% YoY). Core+ behavioral subscribers reached 541K (+13.9% YoY), marking third consecutive quarter of sequential growth. The company reduced term loan principal by $41.4M in Q2 (via $36.8M cash prepayment), bringing outstanding debt to $424M from $465M at year-end 2025. Q2 Adjusted EBITDA was $39.8M (24.5% margin); company reaffirmed FY 2026 revenue guidance of $620–635M and Adjusted EBITDA guidance of $105–115M.
Why this rating
Solid operational execution (Core+ growth, clinical traction, debt reduction, positive cash flow) partially offset by declining total subscribers (2.5M, -21% YoY) and 6M net loss of $37.9M. Results are meaningful but within guidance; reaffirm shows stability, not growth reset. Debt reduction valuable for ~$301M market-cap company post-bankruptcy but not transformational.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.